ATF4 and Parkinson disease: Guanabenz, a hypotensive drug acting on the β2 adrenergic receptor, showed enhanced effects [115] and was beneficial in familial ALS [116], VWMD [117] and in PD cellular and animal models, by increasing ATF4 levels, leading to upregulation of parkin [118,119,120].